eXIthera: clinical-stage biotech developing small molecule drugs for the prevention of thrombosis without increased risk of bleeding.
Employees: 11-50
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | Schooner C... | schoonerca... |
Mentions in press and media 2
| Date | Title | Description |
| 18.08.2014 | Exithera raising $9M, develops pill as next-gen anti-stroke medication | eXIthera Pharmaceuticals stroke prevention and antithrombosis drugs are based on the unique pathophysiological role of Factor XI in the initiation of intravascular thrombi without causing undue bleeding. Thrombosis prevention without bleedi... |
| - | Exithera raising $9M, develops pill as next-gen anti-stroke medication | Exithera Pharmaceuticals, a player in the anti-thrombosis and stroke prevention drug space, appears to be in the midst of a $9 million Series B round, according to regulatory filings. It has raised $3 million thus far, the filings said. Las... |